Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 587

Sort by

Sort Order Select

Journal Articles

Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab

Hannah Goulart, Elias Jabbour, Nitin Jain, Farhad Ravandi, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Alex Bataller, Fadi Haddad, Rita Khouri, Jayastu Senapati, Rebecca Garris, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2025-3350

Published: 2025

Journal Articles

Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission

Hannah Goulart, Elias Jabbour, Nitin Jain, Fadi Haddad, Jayastu Senapati, Rita Khouri, Guillermo Garcia-Manero, William Wierda, Farhad Ravandi, Naveen Pemmaraju, Kelly Chien, Rebecca Garris, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 3348.

https://doi.org/10.1182/blood-2025-3348

Published: 2025

Journal Articles

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Blood (2025) 146 (Supplement 1): 81.

https://doi.org/10.1182/blood-2025-81

Published: 2025

Journal Articles

Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

Warren Fiskus, Christopher Mill, Lucia Masarova, Naveen Pemmaraju, Prithviraj Bose, Arnav Gupta, Hanxi Hou, Taghi Manshouri, Jayastu Senapati, Sanam Loghavi, Andrew Dunbar, Claes Wahlestedt, Courtney DiNardo, Kapil Bhalla

Blood (2025) 146 (Supplement 1): 5053.

https://doi.org/10.1182/blood-2025-5053

Published: 2025

Journal Articles

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study

Naveen Pemmaraju, Luca Mazzarella, Giovanni Marconi, David Sallman, Matthew Ulrickson, Roland Walter, Valerio Maisano, Breanne Fishman, Yining Du, Jalaja Potluri, Hagop Kantarjian, Naval Daver

Blood (2025) 146 (Supplement 1): 5195.

https://doi.org/10.1182/blood-2025-5195

Published: 2025

Journal Articles

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

William D. Marrero, Mina Abdelmalek, Farah Al Haj, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sanam Loghavi, Gautam Borthakur, Nicholas Short, Ghayas Issa, Jayastu Senapati, Wei-Ying Jen, Naveen Pemmaraju, Fnu Amritpal Singh, Abhishek Maiti, Guillermo Garcia-Manero, Farhad Ravandi, Naval Daver

Blood (2025) 146 (Supplement 1): 5179.

https://doi.org/10.1182/blood-2025-5179

Published: 2025

Journal Articles

Blinatumomab and ponatinib vs. hyper-CVAD and ponatinib in patients with Philadelphia-chromosome positive acute lymphoblastic leukemia: A propensity score analysis

Koji Sasaki, Hagop Kantarjian, Nicholas Short, Nitin Jain, Xuelin Huang, Farhad Ravandi, William Wierda, Gautam Borthakur, Ghayas Issa, Yesid Alvarado Valero, Naveen Pemmaraju, Guillermo Garcia-Manero, Rebecca Garris, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1578.

https://doi.org/10.1182/blood-2025-1578

Published: 2025

Journal Articles

Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study

Hannah Goulart, Elias Jabbour, Nitin Jain, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Kelly Chien, Fadi Haddad, Jayastu Senapati, Rita Khouri, Farhad Ravandi, Guillermo Garcia-Manero, Rebecca Garris, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 1571.

https://doi.org/10.1182/blood-2025-1571

Published: 2025

Journal Articles

The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study

Hannah Goulart, Hagop Kantarjian, Nitin Jain, Rita Khouri, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Alessandra Ferrajoli, Alex Bataller, Fadi Haddad, Jayastu Senapati, Guillermo Garcia-Manero, Rebecca Garris, Farhad Ravandi, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2025-1567

Published: 2025

Journal Articles

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Hannah Goulart, Hagop Kantarjian, Koji Sasaki, Nitin Jain, Caitlin Rausch, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Danielle Hammond, Mahesh Swaminathan, Rita Khouri, Maro Ohanian, Rebecca Garris, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2025-1566

Published: 2025

Journal Articles

Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens

Grace Park, Hagop Kantarjian, Nicholas Short, Nitin Jain, Farhad Ravandi, Kelly Chien, Jayastu Senapati, Fadi Haddad, Rita Khouri, Tapan Kadia, Naval Daver, Courtney DiNardo, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Naveen Pemmaraju, Rebecca Garris, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2025-1544

Published: 2025

Journal Articles

Dose intensive regimen of CK0804 tregs in myelofibrosis

Lucia Masarova, Mehrdad Abedi, Naveen Pemmaraju, Prithviraj Bose, Tapan Kadia, Jo Ishizawa, Guillermo Montalban-Bravo, Tara Sadeghi, Simrit Parmar, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5602.

https://doi.org/10.1182/blood-2025-5602

Published: 2025

Journal Articles

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2075.

https://doi.org/10.1182/blood-2025-2075

Published: 2025

Journal Articles

Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion

Francisco Rodolfo Saenz, Bouthaina Dabaja, Naval Daver, Farhad Ravandi, Susan Wu, Timothy Lin, Penny Fang, Jillian Gunther, Tapan Kadia, Gautam Borthakur, William Wierda, Elias Jabbour, Naveen Pemmaraju, Chelsea Pinnix, Hagop Kantarjian, Nitin Jain, Michael Spiotto

Blood (2025) 146 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2025-1727

Published: 2025

Journal Articles

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

Jayastu Senapati, Hagop Kantarjian, Tapan Kadia, Naveen Pemmaraju, Courtney DiNardo, Naval Daver, Andres Quesada, Austin Wilson, Kayla Farish, Fadi Haddad, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur

Blood (2025) 146 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2025-1724

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Roberta S. Azevedo, Guillermo Garcia-Manero, Elias Jabbour, Danielle Hammond, Kelly Chien, Tapan Kadia, Steven Kornblau, Farhad Ravandi, Gautam Borthakur, Naveen Pemmaraju, Hyunsoo Hwang, Xuelin Huang, Heather Schneider, Meghan Meyer, Guillermo Montalban-Bravo

Blood (2025) 146 (Supplement 1): 5645.

https://doi.org/10.1182/blood-2025-5645

Published: 2025

Journal Articles

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3867.

https://doi.org/10.1182/blood-2025-3867

Published: 2025

Journal Articles

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Blood (2025) 146 (Supplement 1): 3857.

https://doi.org/10.1182/blood-2025-3857

Published: 2025

Journal Articles

Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3849.

https://doi.org/10.1182/blood-2025-3849

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab

Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

Blinatumomab and ponatinib vs. hyper-CVAD and ponatinib in patients with Philadelphia-chromosome positive acute lymphoblastic leukemia: A propensity score analysis

Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study

The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens

Dose intensive regimen of CK0804 tregs in myelofibrosis

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only